Hypertension and Long-Term Adverse Clinical Outcomes in MASLD: Sensitivity Analyses for Unmeasured or Uncontrolled Confounding Guiying Gao, Xiuhong Wang, Ruizhe Huang, Jing Cao Journal of Hepatology.2026;[Epub] CrossRef
Extracellular Vesicles: Orchestrators of Intrahepatic and Systemic Crosstalk in Metabolic Dysfunction-Associated Steatotic Liver Disease Yu Lei, Mei Liu, Xiang Tao Pharmaceutics.2026; 18(1): 116. CrossRef
Hydrogel-Based Therapeutic Strategies for Post-Cholecystectomy NAFLD: Targeting Bile Acid Signaling, Gut Microbiota, Inflammation, and Hepatic Fibrosis Georgiana-Andreea Marinescu, Alexandra-Daniela Rotaru-Zavaleanu, Emil-Tiberius Trasca, Elena-Irina Caluianu, Oana Taisescu, Andrei Gresita, Madalina Iuliana Musat, Dumitru Radulescu, Razvan Mercut, Citto-Iulian Taisescu Gels.2026; 12(2): 179. CrossRef
Probiotic-Derived Strain-Specific Metabolites Ameliorate Metabolic Dysfunction–Associated Steatotic Liver Disease through Modulation of the Gut-Liver Axis Sang Jun Yoon, Jieun Choi, Sung-Min Won, Jeong Seok Yu, Hee Young Kim, Hyun Chae Joung, In Gyu Park, Jung A Eom, Sang Hak Han, Do Yup Lee, Ki Tae Suk Probiotics and Antimicrobial Proteins.2025;[Epub] CrossRef
From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease Gianmario Forcina, Vittoria Frattolillo, Maria De Cesare, Assunta Floriano, Rosamaria Palma, Federica Casamassima, Mario Bartiromo, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1329. CrossRef
Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease” Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 1050. CrossRef
Nutrition and dietary interventions are a central component in the pathophysiology, but also a cornerstone in the management of patients with non-alcoholic fatty liver disease (NAFLD). Summarizing our rapidly advancing understanding of how our diet influences our metabolism and focusing on specific effects on the liver, we provide a comprehensive overview of dietary concepts to counteract the increasing burden of NAFLD. Specifically, we emphasize the importance of dietary calorie restriction independently of the macronutrient composition together with adherence to a Mediterranean diet low in added fructose and processed meat that seems to exert favorable effects beyond calorie restriction. Also, we discuss intermittent fasting as a type of diet specifically tailored to decrease liver fat content and increase ketogenesis, awaiting future study results in NAFLD. Finally, personalized dietary recommendations could be powerful tools to increase the effectiveness of dietary interventions in patients with NAFLD considering the genetic background and the microbiome, among others.
Citations
Citations to this article as recorded by
Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi Journal of Advanced Research.2026; 80: 893. CrossRef
Ultrafiltered mulberry leaf glutelin mitigates non-alcoholic fatty liver disease through modulation of lipid metabolism, inflammation, and serum metabolomics Mingxi Li, Hongyan Li, Jia Zou, Renqin Li, Haoqi Zhang, Wenhan Yang, Xiyang Wu, Chongzhen Sun Food & Function.2026; 17(2): 819. CrossRef
Long-Term Fructose Intake Induces Moderate Liver Inflammation but Does not Overlap with the Detrimental Effects of the Ketogenic Diet on Hepatic Steatosis in Rats Júlia Galbiati de Souza, Glaucivan Gomes Gurgel, Fernanda Marques Rodrigues, Ribanna Aparecida Marques Braga, Rosana Aparecida Manólio Soares, Luís Alberto de Pádua Covas Lage, Iberê Cauduro Soares, Débora Levy, Nágila Raquel Teixeira Damasceno Inflammation.2026;[Epub] CrossRef
Effects of Intermittent Calorie Restriction in Nondiabetic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Han Ah Lee, Hyeyoung Moon, Yuri Kim, Jeong Kyong Lee, Hye Ah Lee, Hwi Young Kim Clinical Gastroenterology and Hepatology.2025; 23(1): 114. CrossRef
Total choline intake, liver fibrosis and the progression of metabolic dysfunction-associated steatotic liver disease: Results from 2017 to 2020 NHANES Siraphat Taesuwan, Matina Kouvari, Andrew J. McKune, Demosthenes B. Panagiotakos, Julaluk Khemacheewakul, Noppol Leksawasdi, Pornchai Rachtanapun, Nenad Naumovski Maturitas.2025; 191: 108150. CrossRef
Treating Metabolic Dysregulation and Senescence by Caloric Restriction: Killing Two Birds with One Stone? Lara Russo, Serena Babboni, Maria Grazia Andreassi, Jalil Daher, Paola Canale, Serena Del Turco, Giuseppina Basta Antioxidants.2025; 14(1): 99. CrossRef
Monascus pilosus SWM-008 red mold rice and its components, monascinol and monascin, reduce obesity in a high-fat diet-induced rat model through synergistic modulation of gut microbiota and anti-lipogenesis Chin-Feng Liu, Hui-Tzu Chuang, Chia-Shu Wang, Ya-Wen Hsu, Tzu-Ming Pan, Chun-Lin Lee Food & Function.2025; 16(3): 966. CrossRef
Dietary and lifestyle indices for hyperinsulinemia and odds of MAFLD in overweight and obese children and adolescents Ali Nikparast, Maryam Razavi, Parmis Mirzaei, Pooneh Dehghan, Mahdi Amani Farani, Golaleh Asghari Scientific Reports.2025;[Epub] CrossRef
YouTube as a Source of Information for Dietary Guidance and Advisory Content in the Management of Non-Alcoholic Fatty Liver Disease Kagan Tur Healthcare.2025; 13(4): 351. CrossRef
Sex-Specific Biochemical and Histopathological Effects of Chronic Meat-Based vs. Plant-Based Burger Consumption in a Rodent Model Cristina Filip, Ruxandra Ștefănescu, Bianca-Eugenia Ősz, Amalia Pușcaș, Corneliu Tanase, Adela Nechifor-Boilă, Amelia Tero-Vescan Foods.2025; 14(5): 888. CrossRef
Non-alcoholic fatty liver disease: diet therapy and pharmacotherapy M. L. Maksimov, V. A. Dudareva, V. O. Vovk, V. I. Sklyarova, S. O. Ivashchenko, A. A. Shikaleva Terapevt (General Physician).2025; (3): 37. CrossRef
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen Clinical and Molecular Hepatology.2025; 31(2): e186. CrossRef
An umbrella review of the association between dietary factors and hepatocellular carcinoma risk Han Li, Qi-Hang Cao, Hui Liu, Lun-Jie Yan, Zi-Niu Ding, Han-Chao Wang, Rui Dong, Bao-Wen Tian, Cheng-Long Han, Zhao-Ru Dong, Long-Shan Yang, Xin-Cheng Mao, Yu-Chuan Yan, Dong-Xu Wang, Tao Li Food & Function.2025; 16(10): 3879. CrossRef
ASS1 is a hub gene and possible therapeutic target for regulating metabolic dysfunction-associated steatotic liver disease modulated by a carbohydrate-restricted diet Shaojun Chen, Yanhua Bi, Lihua Zhang Molecular Diversity.2025; 29(4): 3717. CrossRef
2,5-Dihydroxybenzoic Acid Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Targeting the CCL2-CCR2 Axis to Reduce Lipid Accumulation Chien-Yun Hsiang, Kuang-Ting Hsu, Hsin-Yi Lo, Yun-Jhu Hou, Tin-Yun Ho Nutrients.2025; 17(11): 1835. CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi Nutrients.2025; 17(13): 2211. CrossRef
Amaranthus graecizans L. Mitigates Hyperlipidemia-Induced Nonalcoholic Fatty Liver Disease in Experimental Rats: Future Pharmaceuticals Nadiah S. Alzahrani, Bayan Aljahdali, Aeshah Alhosain, Abeer Abdullah Alasmari, Touseef Amna, Soha Mohamed Yousef Pharmaceuticals.2025; 18(8): 1196. CrossRef
Higher Food Inflammation Index Is Linearly Associated With Higher Risk of MASLD: A Cross‐Sectional Study Based on the NHANES (1999–2020) Qingwan Yang, Xin Cai, Zhenghua Xiao Food Science & Nutrition.2025;[Epub] CrossRef
Comparative efficacy of different diet modalities on metabolic profiles and liver functions in metabolic dysfunction-associated fatty liver disease: a network meta-analysis Jiahui Zou, Fei Tian, Shuqing Cui, Jing Hou, Zhenhua Li, Yaochen Wei, Haozhe Cui, Yunpeng Li, Shuanghao Zhou, Zechao He, Xiangming Ma BMC Gastroenterology.2025;[Epub] CrossRef
Ramadan fasting model exerts hepatoprotective, anti-obesity, and anti-hyperlipidemic effects in an experimentally-induced nonalcoholic fatty liver in rats Abeer A. Alasmari, Abdulrahman S. Al-Khalifah, Ahmed S. BaHammam, Noura M. S. Alshiban, Ahmad T. Almnaizel, Hesham S. Alodah, Maha H. Alhussain Saudi Journal of Gastroenterology.2024; 30(1): 53. CrossRef
Decrease in Leptin Expression in the Liver after Prolonged Every-Other-Day Feeding in C57Bl/6 Male Mice Katarzyna Piotrowska, Maciej Tarnowski, Patrycja Tomasiak, Michał Czerewaty, Katarzyna Zgutka, Andrzej Pawlik Physiologia.2024; 4(1): 100. CrossRef
Beneficial effects of intermittent fasting on nonalcoholic fatty liver disease: a narrative review Qingxuan Deng, Ruyue Lv, Haoqi Zou, Tangbin Zou Egyptian Liver Journal.2024;[Epub] CrossRef
Synergistic Effects of Fructose and Food Preservatives on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): From Gut Microbiome Alterations to Hepatic Gene Expression Tomas Hrncir, Eva Trckova, Lucia Hrncirova Nutrients.2024; 16(21): 3722. CrossRef
The Interplay Between Depression, Probiotics, Diet, Immunometabolic Health, the Gut, and the Liver—A Secondary Analysis of the Pro-Demet Randomized Clinical Trial Oliwia Gawlik-Kotelnicka, Jakub Rogalski, Karolina H. Czarnecka-Chrebelska, Jacek Burzyński, Paulina Jakubowska, Anna Skowrońska, Dominik Strzelecki Nutrients.2024; 16(23): 4024. CrossRef
Prevalence of Liver Steatosis Among Workers in Ouagadougou and Associated Factors: A Cross‐Sectional Study Delphine Napon‐Zongo, Jeoffray Diendere, Armel M. Sanou, Abou Coulibaly, Abdoulaye Dera, Nina G. M. Ouattara, Augustin N. Zeba, Seni Kouanda JGH Open.2024;[Epub] CrossRef
Dietary modulation of gut microbiota affects susceptibility to drug-induced liver injury Han Pan, Delei Song, Zhiyi Wang, Xin Yang, Pei Luo, Wei Li, Yan Li, Mengxue Gong, Chenhong Zhang Gut Microbes.2024;[Epub] CrossRef
Non-alcoholic fatty liver disease in people with normal body weight S. V. Turkina, I. A. Tyshchenko, M. N. Titarenko Experimental and Clinical Gastroenterology.2024; (10): 36. CrossRef
Optimal choice of diet and food for NAFLD G. V. Shavkuta, L. B. Lazebnik Experimental and Clinical Gastroenterology.2024; (10): 98. CrossRef
Effect of Nut Consumption on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis Ling Pan, Jing Sui, Ying Xu, Qun Zhao Nutrients.2023; 15(10): 2394. CrossRef
Synergistic Effect of Diet and Physical Activity on a NAFLD Cohort: Metabolomics Profile and Clinical Variable Evaluation Francesco Maria Calabrese, Giuseppe Celano, Caterina Bonfiglio, Angelo Campanella, Isabella Franco, Alessandro Annunziato, Gianluigi Giannelli, Alberto Ruben Osella, Maria De Angelis Nutrients.2023; 15(11): 2457. CrossRef
Diet and non-alcoholic fatty liver disease, a short narrative review W.J. Kwanten Acta Gastro Enterologica Belgica.2023; 86(2): 306. CrossRef
β-hydroxybutyrate: A crucial therapeutic target for diverse liver diseases Ke Li, Wen-hong Wang, Jia-bin Wu, Wei-hua Xiao Biomedicine & Pharmacotherapy.2023; 165: 115191. CrossRef
Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease” Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 1050. CrossRef
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with a prevalence that is increasing in parallel with the global rise in obesity and type 2 diabetes mellitus. The pathogenesis of NAFLD is complex and multifactorial, involving environmental, genetic and metabolic factors. The role of the diet and the gut microbiome is gaining interest as a significant factor in NAFLD pathogenesis. Dietary factors induce alterations in the composition of the gut microbiome (dysbiosis), commonly reflected by a reduction of the beneficial species and an increase in pathogenic microbiota. Due to the close relationship between the gut and liver, altering the gut microbiome can affect liver functions; promoting hepatic steatosis and inflammation. This review summarises the current evidence supporting an association between NAFLD and the gut microbiome and dietary factors. The review also explores potential underlying mechanisms underpinning these associations and whether manipulation of the gut microbiome is a potential therapeutic strategy to prevent or treat NAFLD.
Citations
Citations to this article as recorded by
A Review of the Gut Microbiome and Its Role in Non-alcoholic Fatty Liver Disease Fahad Alfhaid Advances in Human Biology.2026; 16(1): 11. CrossRef
Low Serum sRAGE and MASLD Are Associated and Share a Similar Gut Microbiota Profile: A Prospective and Cross‐Sectional Analysis Laura Sol Grinshpan, Dana Ivancovsky‐Wajcman, Oren Tirosh, Michal Verman, Naomi Fliss‐Isakov, Muriel Webb, Oren Shibolet, Maya Ofek‐Lalzar, Revital Kariv, Shira Zelber‐Sagi Liver International.2026;[Epub] CrossRef
10-hydroxy-2(E)-decenoic acid attenuates metabolic dysfunction–associated steatotic liver disease via modulation of the gut microbiota–bile acid–FXR axis Xinyu Yu, Meifei Zhu, Kangli Wang, Bin Yuan, Yuanyuan Lu, Shanshan Li, Fuliang Hu Food Bioscience.2026; 78: 108532. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa Mohamed El-Kassas, C. Wendy Spearman, Manal El-Sayed, Zobair M. Younossi Clinics in Liver Disease.2026;[Epub] CrossRef
Gut-Derived Hippuric Acid Alleviates Hepatic Lipid Metabolism via UGDH/FOXK1/CD36 Axis in Obese Mice Shuai Chen, Jiaming Xue, Yuancheng Shao, Hanyang Liu, Fangmin Zhou, Xihan Gu, Gang Zhou, Tianhan Xu, Dongmei Wang, Liming Tang Drug Design, Development and Therapy.2026; Volume 20: 1. CrossRef
Supragingival
Actinomyces naeslundii
aggravates metabolic dysfunction-associated fatty liver disease via the oral–gut axis
Ye Tu, Zhanyi Chen, Meiling Jing, Wenduo Tan, Danni Huang, Jin Xu, Min Wang, Hao Li, Yueyi Yang, Xiaoyu Liu, Xuchen Hu, Yihuai Pan, Chenguang Niu, Zhengwei Huang Journal of Oral Microbiology.2026;[Epub] CrossRef
Multistrain Probiotics Alleviate Diarrhea by Modulating Microbiome-Derived Metabolites and Serotonin Pathway Jin-Ju Jeong, Yoo-Jeong Jin, Raja Ganesan, Hee Jin Park, Byeong Hyun Min, Min Kyo Jeong, Sang Jun Yoon, Mi Ran Choi, Satya Priya Sharma, You Jin Jang, Uigi Min, Jong-Hyun Lim, Kyeong Min Na, Jieun Choi, Sang Hak Han, Young Lim Ham, Do Yup Lee, Byung-Yong Probiotics and Antimicrobial Proteins.2025; 17(5): 2894. CrossRef
The causal relationship of cigarette smoking to metabolic disease risk and the possible mediating role of gut microbiota Jingda Zhang, Lin Hou, Shanxiang Lei, Yan Li, Guogang Xu Ecotoxicology and Environmental Safety.2025; 290: 117522. CrossRef
SMALL INTESTINAL BACTERIAL OVERGROWTH IN THE INTESTINE AND MICROBIOME ALTERATIONS AS A RISK FACTOR FOR LIPID METABOLISM DISORDERS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE Kh. B. Kvit, N. V. Kharchenko Art of Medicine.2025; : 38. CrossRef
Exploration of Early Diagnostic Biomarkers for Intestinal Barrier Dysfunction in Non-Alcoholic Fatty Liver Disease 庄巍 李 Advances in Clinical Medicine.2025; 15(02): 315. CrossRef
Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease Sang Yoon Lee, Su-Been Lee, Goo-Hyun Kwon, Seol Hee Song, Jeong Ha Park, Min Ju Kim, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Satya Priya Sharma, Ki Tae Journal of Microbiology.2025; 63(2): e2411002. CrossRef
Gut microbiome alterations in immune thrombocytopenia: a systematic review of current evidence Alireza Khiabani, Roohollah Mirzaee Khalilabadi, Hajar Mardani Valandani, Zahra Khoshnegah, Alireza Khanahmad, Hojat Shahraki, Najmeh Nezamabadipour, Alireza Farsinejad, Mehran Rahimlou Frontiers in Medicine.2025;[Epub] CrossRef
The crosstalk between gut microbiota and microbiota-derived metabolites in hepatocellular carcinoma Sang Jun Yoon, Seul Ki Han, Tae Suk Kim, Ki Tae Suk, Dae Hee Choi, Young Don Kim, Moon Young Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim Critical Reviews in Microbiology.2025; 51(6): 1315. CrossRef
The newly proposed dietary index for gut microbiota and its association with the risk of nonalcoholic fatty liver disease: the mediating role of body mass index Shengnan Meng, Luonan Li, Shijie Yin, Yuxuan Zhao, Yaning Liu, Yuxi Zhang, Xiaolin Zhang, Fengxue Yu Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Gut microbiota and metabolomics in metabolic dysfunction-associated fatty liver disease: interaction, mechanism, and therapeutic value Luyu Wang, Hongtao Wang, Jian Wu, Changyi Ji, Ying Wang, Mengmeng Gu, Miaomiao Li, Hongwei Yang Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
Phocaeicola dorei
ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
Jieun Choi, Ye Rin Choi, Min Kyo Jeong, Hyun Ho Song, Jeong Seok Yu, Seol Hui Song, Jeong Ha Park, Min Ju Kim, Hyunjoon Park, Young Lim Ham, Sang Hak Han, Dong Joon Kim, Do Yup Lee, Ki Tae Suk Gut Microbes.2025;[Epub] CrossRef
Fibroblast growth factor receptor inhibitors ameliorate metabolic dysfunction-associated steatohepatitis by modulating the glycine-glutathione-gut microbiota axis Hailong Li, Xiaoman Ye, Yayue Hu, Yingjun Wang, Yuting Ding, Ying Yang, Ruiqi Mao, Xi Wu, Huixuan Dong, Kaijun Qiu, Xiaohe Li, Honggang Zhou, Guang Yang, Fubao Zhang, Cheng Yang Free Radical Biology and Medicine.2025; 240: 410. CrossRef
Visiting MASLD through the lens of sex, immunity, and microbial interactions Snehanjali Puhan, Smaroki Smruti Rekha, Kartika Sahu, Tanuja Mohanty, Arka Jyoti De, Ankita Das, Palok Aich Discover Medicine.2025;[Epub] CrossRef
The AhR/IL-22 axis in chronic gut inflammation: unraveling mechanisms and therapeutic prospects Huimin Kang, Zheng Chen, Baodong Wang, Zhiyun Chen Frontiers in Immunology.2025;[Epub] CrossRef
Food Minor Bioactive Compounds of Polyphenolic and Polyprenolic Nature Are Promising Agents for the Prevention and Therapy of Non-Alcoholic Fatty Liver Disease Anastasiya Balakina, Yuliya Sidorova, Nikita Petrov, Vladimir Shipelin Molecules.2025; 30(18): 3791. CrossRef
From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease Gianmario Forcina, Vittoria Frattolillo, Maria De Cesare, Assunta Floriano, Rosamaria Palma, Federica Casamassima, Mario Bartiromo, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1329. CrossRef
Ultra-processed food consumption and non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance: A systematic review Laura Sol Grinshpan, Sigal Eilat-Adar, Dana Ivancovsky-Wajcman, Revital Kariv, Michal Gillon-Keren, Shira Zelber-Sagi JHEP Reports.2024; 6(1): 100964. CrossRef
Healthy diet intervention reverses the progression of NASH through gut microbiota modulation Suraphan Panyod, Wei-Kai Wu, Meng-Yun Hu, Huai-Syuan Huang, Rou-An Chen, Yi-Hsun Chen, Ting-Chin David Shen, Chi-Tang Ho, Chun-Jen Liu, Hsiao-Li Chuang, Chi-Chang Huang, Ming-Shiang Wu, Lee-Yan Sheen, Wei-Hua Chen Microbiology Spectrum.2024;[Epub] CrossRef
The Current and Future State of Microbiome Therapeutics in Liver Disease Patricia P. Bloom, Jasmohan S. Bajaj American Journal of Gastroenterology.2024; 119(1S): S36. CrossRef
Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon Jorge Arnold, Francisco Idalsoaga, Luis Antonio Díaz, Daniel Cabrera, Francisco Barrera, Juan Pablo Arab, Marco Arrese Current Hepatology Reports.2024; 23(1): 204. CrossRef
Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation Byeong Hyun Min, Shivani Devi, Goo Hyun Kwon, Haripriya Gupta, Jin-Ju Jeong, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Hee Jin Park, Jung A Eom, Min Kyo Jeong, Ji Ye Hyun, Nattan Stalin, Tae-Sik Park, Jieun Choi, Do Yup Lee, Sang Hak H Gut Microbes.2024;[Epub] CrossRef
Food for thought: Making the case for food produced via regenerative agriculture in the battle against non-communicable chronic diseases (NCDs) Davendra Ramkumar, Aileen Marty, Japhia Ramkumar, Holly Rosencranz, Radhika Vedantham, Modan Goldman, Erin Meyer, Jasia Steinmetz, Amy Weckle, Kelly Bloedorn, Carl Rosier One Health.2024; 18: 100734. CrossRef
Gestational supplementation of Bifidobacterium, Lactobacillus, and Streptococcus thermophilus attenuates hepatic steatosis in offspring mice through promoting fatty acid β‐oxidation Hangjun Chen, Qiongmei Wu, Xingyi Chen, Xinxue Yu, Hanqing Zhao, Qiaoli Huang, Yurong Huang, Jinting Wang, Xueyi Huang, Jun Wei, Feng Wu, Xiaomin Xiao, Lijun Wang Journal of Food Science.2024; 89(5): 3064. CrossRef
Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study Nicolás Ortiz-López, Ana María Madrid, Larissa Aleman, Alejandra Zazueta, Gladys Smok, Lucía Valenzuela-Pérez, Jaime Poniachik, Caroll J. Beltrán Frontiers in Medicine.2024;[Epub] CrossRef
Developmental Programming of the Fetal Immune System by Maternal Western-Style Diet: Mechanisms and Implications for Disease Pathways in the Offspring Benjamin N. Nelson, Jacob E. Friedman International Journal of Molecular Sciences.2024; 25(11): 5951. CrossRef
Quantification of gut microbiome metabolites using chemical isotope derivatization strategy combined with LC-MS/MS: Application in neonatal hypoxic-ischemic encephalopathy rat model Fangbo Xia, Peng Cui, Ling Liu, Junhe Chen, Qiqi Zhou, Qian Wang, Hongwei Zhou Journal of Pharmaceutical and Biomedical Analysis.2024; 248: 116312. CrossRef
An examination of global research trends for exploring the associations between the gut microbiota and nonalcoholic fatty liver disease through bibliometric and visualization analysis Sa’ed H. Zyoud, Samer O. Alalalmeh, Omar E. Hegazi, Muna Shakhshir, Faris Abushamma, Samah W. Al-Jabi Gut Pathogens.2024;[Epub] CrossRef
Gut Dysbiosis Shaped by Cocoa Butter-Based Sucrose-Free HFD Leads to Steatohepatitis, and Insulin Resistance in Mice Shihab Kochumon, Md. Zubbair Malik, Sardar Sindhu, Hossein Arefanian, Texy Jacob, Fatemah Bahman, Rasheeba Nizam, Amal Hasan, Reeby Thomas, Fatema Al-Rashed, Steve Shenouda, Ajit Wilson, Shaima Albeloushi, Nourah Almansour, Ghadeer Alhamar, Ashraf Al Madh Nutrients.2024; 16(12): 1929. CrossRef
Ginger essential oil prevents NASH progression by blocking the NLRP3 inflammasome and remodeling the gut microbiota-LPS-TLR4 pathway in mice Suraphan Panyod, Wei-Kai Wu, Ya-Chi Hsieh, Yea-Jing Tseng, Sin-Yi Peng, Rou-An Chen, Huai-Syuan Huang, Yi-Hsun Chen, Ting-Chin David Shen, Chi-Tang Ho, Chun-Jen Liu, Hsiao-Li Chuang, Chi-Chang Huang, Ming-Shiang Wu, Lee-Yan Sheen Nutrition & Diabetes.2024;[Epub] CrossRef
Altered gut microbial profile accompanied by abnormal short chain fatty acid metabolism exacerbates nonalcoholic fatty liver disease progression Chao Yang, Jiale Wu, Ligang Yang, Qiaosheng Hu, Lihua Li, Yafang Yang, Jing Hu, Da Pan, Qing Zhao Scientific Reports.2024;[Epub] CrossRef
Regulation of endotoxemia through the gut microbiota: The role of the Mediterranean diet and its components Jing Kong, Juan Yang, Cong He, Bingduo Zhou, Shengquan Fang, Manisha Salinas, Arya B. Mohabbat, Brent A. Bauer, Xiaosu Wang APMIS.2024; 132(12): 948. CrossRef
Insights of gut-liver axis in hepatic diseases: Mechanisms, clinical implications, and therapeutic potentials Naveen Jeyaraman, Madhan Jeyaraman, Tejaswin Mariappan, Sathish Muthu, Swaminathan Ramasubramanian, Shilpa Sharma, Gabriel Silva Santos, Lucas Furtado da Fonseca, José Fábio Lana World Journal of Gastrointestinal Pharmacology and Therapeutics.2024;[Epub] CrossRef
Stage dependent microbial dynamics in hepatocellular carcinoma and adjacent normal liver tissues Hee Eun Jo, Sophallika Khom, Sumi Lee, Su Hyeon Cho, Shin Young Park, Ga Ram You, Hyosin Kim, Nah Ihm Kim, Jae-Ho Jeong, Jae Hyun Yoon, Misun Yun Scientific Reports.2024;[Epub] CrossRef
Convergence of Alcohol Consumption and Dietary Quality in US Adults Who Currently Drink Alcohol: An Analysis of Two Core Risk Factors of Liver Disease Peng-Sheng Ting, Wei-Ting Lin, Suthat Liangpunsakul, Madeline Novack, Chiung-Kuei Huang, Hui-Yi Lin, Tung-Sung Tseng, Po-Hung Chen Nutrients.2024; 16(22): 3866. CrossRef
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, Ramón Bataller, Marco Arrese Nature Reviews Gastroenterology & Hepatology.2023; 20(12): 764. CrossRef
Elevated serum levels of diamine oxidase, D-lactate and lipopolysaccharides are associated with metabolic-associated fatty liver disease Ruike Zhang, Ya-nan Chen, Jixia Zhang, Jing Liu European Journal of Gastroenterology & Hepatology.2023; 35(1): 94. CrossRef
Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol Ming Yang, Xiaoqiang Qi, Nan Li, Jussuf T. Kaifi, Shiyou Chen, Andrew A. Wheeler, Eric T. Kimchi, Aaron C. Ericsson, R. Scott Rector, Kevin F. Staveley-O’Carroll, Guangfu Li Nature Communications.2023;[Epub] CrossRef
The identification of metabolites from gut microbiota in NAFLD via network pharmacology Ki-Kwang Oh, Haripriya Gupta, Byeong Hyun Min, Raja Ganesan, Satya Priya Sharma, Sung Min Won, Jin Ju Jeong, Su Been Lee, Min Gi Cha, Goo Hyun Kwon, Min Kyo Jeong, Ji Ye Hyun, Jung A Eom, Hee Jin Park, Sang Jun Yoon, Mi Ran Choi, Dong Joon Kim, Ki Tae Suk Scientific Reports.2023;[Epub] CrossRef
Comparison between obese and non-obese nonalcoholic fatty liver disease Wah-Kheong Chan Clinical and Molecular Hepatology.2023; 29(Suppl): S58. CrossRef
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef
MicroRNA‐29a Compromises Hepatic Adiposis and Gut Dysbiosis in High Fat Diet‐Fed Mice via Downregulating Inflammation Ya‐Ling Yang, Ying‐Hsien Huang, Feng‐Sheng Wang, Ming‐Chao Tsai, Chien‐Hung Chen, Wei‐Shiung Lian Molecular Nutrition & Food Research.2023;[Epub] CrossRef
Valuable effects of lactobacillus and citicoline on steatohepatitis: role of Nrf2/HO-1 and gut microbiota Ahmed M. El-Baz, Amira M. El-Ganiny, Doaa Hellal, Hala M. Anwer, Hend A. Abd El-Aziz, Ibrahim E. Tharwat, Mohamed A. El-Adawy, Shehab El-Din M. Helal, Menna Tallah A. Mohamed, Tassnim M. Azb, Hanya M. Elshafaey, AbdulRahman A. Shalata, Sahar M. Elmeligi, AMB Express.2023;[Epub] CrossRef
Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients Christoph Roderburg, Sarah Krieg, Andreas Krieg, Sascha Vaghiri, Raphael Mohr, Marcel Konrad, Mark Luedde, Tom Luedde, Karel Kostev, Sven H. Loosen Clinical Research in Cardiology.2023; 112(10): 1446. CrossRef
Blueberry and Blackberry Anthocyanins Ameliorate Metabolic Syndrome by Modulating Gut Microbiota and Short-Chain Fatty Acids Metabolism in High-Fat Diet-Fed C57BL/6J Mice Lanlan Du, Han Lü, Yan Chen, Xiaohua Yu, Tunyu Jian, Huifang Zhao, Wenlong Wu, Xiaoqin Ding, Jian Chen, Weilin Li Journal of Agricultural and Food Chemistry.2023; 71(40): 14649. CrossRef
The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status Josip Stojic, Michał Kukla, Ivica Grgurevic Diagnostics.2023; 13(18): 2960. CrossRef
Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease” Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 1050. CrossRef
A High-Fat Diet Increases the Characteristics of Gut Microbial Composition and the Intestinal Damage Associated with Non-Alcoholic Fatty Liver Disease Xiaoyang Zhu, Jiajia Cai, Yifu Wang, Xinyu Liu, Xiaolei Chen, Haifei Wang, Zhengchang Wu, Wenbin Bao, Hairui Fan, Shenglong Wu International Journal of Molecular Sciences.2023; 24(23): 16733. CrossRef
Preventive Effects of Apple Polyphenol Extract on High-Fat-Diet-Induced Hepatic Steatosis Are Related to the Regulation of Hepatic Lipid Metabolism, Autophagy, and Gut Microbiota in Aged Mice Yan Yin, Yisha Xie, Zhengli Wu, Qingfan Qian, Hao Yang, Shilan Li, Xinli Li Journal of Agricultural and Food Chemistry.2023; 71(50): 20011. CrossRef
Design and Usability Evaluation of a Self-Care Application for Non-Alcoholic Fatty Liver Disease Patients with Overweight: Approach Leveraging Behavior Change Techniques (Preprint) Azam Kheirdoust, Mohammad Reza Mazaheri Habibi, Mohsen Nematy, Ali Jafarzadeh Esfahani, Kosar Ghaddaripour, Saeid Eslami JMIR Human Factors.2023;[Epub] CrossRef
The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases Lingxuan An, Ulrich Wirth, Dominik Koch, Malte Schirren, Moritz Drefs, Dionysios Koliogiannis, Hanno Nieß, Joachim Andrassy, Markus Guba, Alexandr V. Bazhin, Jens Werner, Florian Kühn Journal of Gastrointestinal Surgery.2022; 26(3): 671. CrossRef
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease Alessandro Mantovani, Christopher D. Byrne, Giovanni Benfari, Stefano Bonapace, Tracey G. Simon, Giovanni Targher Journal of the American College of Cardiology.2022; 79(2): 180. CrossRef
Oxidative Stress in Non-Alcoholic Fatty Liver Disease Carlo Smirne, Eleonora Croce, Davide Di Benedetto, Vincenzo Cantaluppi, Cristoforo Comi, Pier Paolo Sainaghi, Rosalba Minisini, Elena Grossini, Mario Pirisi Livers.2022; 2(1): 30. CrossRef
Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study Byoungduck Han, Gyu Bae Lee, Sun Young Yim, Kyung-Hwan Cho, Koh Eun Shin, Jung-Hwan Kim, Yong-Gyu Park, Kyung-Do Han, Yang-Hyun Kim Diagnostics.2022; 12(3): 663. CrossRef
Pterostilbene and Its Derivative 3′-Hydroxypterostilbene Ameliorated Nonalcoholic Fatty Liver Disease Through Synergistic Modulation of the Gut Microbiota and SIRT1/AMPK Signaling Pathway Hui-Yun Tsai, Yu-Yuan Shih, Yao-Tsung Yeh, Cheng-Hsieh Huang, Chorng-An Liao, Chun-Yi Hu, Kalyanam Nagabhushanam, Chi-Tang Ho, Yu-Kuo Chen Journal of Agricultural and Food Chemistry.2022; 70(16): 4966. CrossRef
The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats Yufan Dai, Wenyu Zhu, Jiaxuan Zhou, Tao Shen Brazilian Journal of Medical and Biological Research.2022;[Epub] CrossRef
Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Mira Kang, Eliseo Guallar, Yun Soo Hong, Kyung Hyun Lee, Jiyeon Park, Juhee Cho, Geum‐Youn Gwak Hepatology.2022; 76(6): 1746. CrossRef
The Role of Rumen Microbiota and Its Metabolites in Subacute Ruminal Acidosis (SARA)-Induced Inflammatory Diseases of Ruminants Yunhe Fu, Yuhong He, Kaihe Xiang, Caijun Zhao, Zhaoqi He, Min Qiu, Xiaoyu Hu, Naisheng Zhang Microorganisms.2022; 10(8): 1495. CrossRef
Oral administration of branched-chain amino acids ameliorates high-fat diet-induced metabolic-associated fatty liver disease via gut microbiota-associated mechanisms Ranran Zhang, Hongna Mu, Ziyun Li, Jie Zeng, Qi Zhou, Hongxia Li, Siming Wang, Xianghui Li, Xianghui Zhao, Liang Sun, Wenxiang Chen, Jun Dong, Ruiyue Yang Frontiers in Microbiology.2022;[Epub] CrossRef
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim Hepatology Research.2022; 52(12): 975. CrossRef
The gut microbiota–bile acid axis: A potential therapeutic target for liver fibrosis Yu-Lin Zhang, Zhen-Jiao Li, Hong-Zhong Gou, Xiao-Jing Song, Lei Zhang Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef
The role of the intestinal permeability in the progression of nonalcoholic fatty liver disease in obese children Yu.M. Stepanov, N.Yu. Zavhorodnia, N.O. Zhyhyr GASTROENTEROLOGY.2022; 56(1): 20. CrossRef
The Gut-Liver Axis in Cholestatic Liver Diseases Andreas Blesl, Vanessa Stadlbauer Nutrients.2021; 13(3): 1018. CrossRef
Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease Joo Hyun Oh, Je Hee Lee, Min Seok Cho, Hyeree Kim, Jongsik Chun, Joon Hyeok Lee, Yeup Yoon, Wonseok Kang Nutrients.2021; 13(3): 1013. CrossRef
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach Giovanni Targher, Herbert Tilg, Christopher D Byrne The Lancet Gastroenterology & Hepatology.2021; 6(7): 578. CrossRef
CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload Riina Harjumäki, Chris S. Pridgeon, Magnus Ingelman-Sundberg International Journal of Molecular Sciences.2021; 22(15): 8221. CrossRef
Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases Satya Priya Sharma, Ki Tae Suk, Dong Joon Kim World Journal of Gastroenterology.2021; 27(37): 6161. CrossRef
Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa C Wendy Spearman, Mary Afihene, Omolade Betiku, Bilal Bobat, Lina Cunha, Chris Kassianides, Leolin Katsidzira, Hailemichael D Mekonnen, Ponsiano Ocama, Olusegun Ojo, Imran Paruk, Christian Tzeuton, Mark W Sonderup The Lancet Gastroenterology & Hepatology.2021; 6(12): 1036. CrossRef
Diet-Regulating Microbiota and Host Immune System in Liver Disease Jung A Eom, Goo Hyun Kwon, Na Yeon Kim, Eun Ju Park, Sung Min Won, Jin Ju Jeong, Ganesan Raja, Haripriya Gupta, Yoseph Asmelash Gebru, Satyapriya Sharma, Ye Rin Choi, Hyeong Seop Kim, Sang Jun Yoon, Ji Ye Hyun, Min Kyo Jeong, Hee Jin Park, Byeong Hyun Min International Journal of Molecular Sciences.2021; 22(12): 6326. CrossRef
Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease Li-Hong He, Dun-Han Yao, Ling-Yun Wang, Lei Zhang, Xue-Li Bai Frontiers in Microbiology.2021;[Epub] CrossRef
INSULIN RESISTANCE AS AN INDICATOR OF DIFFERENTIATION FOR THE FORMATION OF RISK GROUPS FOR NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITHOUT TYPE 2 DIABETES MELLITUS, AS A PART OF ONTOLOGICAL MODEL OF NON-ALCOHOLIC FATTY LIVER DISEASE Natalia O. Nosko, Viacheslav V. Kharchenko Wiadomości Lekarskie.2021; 74(10): 2593. CrossRef
Dual role of neutrophils in modulating liver injury and fibrosis during development and resolution of diet-induced murine steatohepatitis Andrea D. Kim, Sung Eun Kim, Aleksandra Leszczynska, Benedikt Kaufmann, Agustina Reca, Dong Joon Kim, Ariel E. Feldstein Scientific Reports.2021;[Epub] CrossRef
Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection Yi Jiang, Salil Chowdhury, Bing-Hong Xu, Mohamad Aghaie Meybodi, Konstantinos Damiris, Samanthika Devalaraju, Nikolaos Pyrsopoulos World Journal of Hepatology.2021; 13(11): 1777. CrossRef
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and affects approximately one third of adults in the United States. The disease is becoming a global epidemic as a result of the rising rates of obesity and metabolic disease. Emerging data suggest weight loss of ≥10% overall body weight is beneficial in resolving steatosis and reversing fibrosis. Prospective trials comparing various diets are limited by lack of sufficient power as well as pre- and post-treatment histopathology, and therefore no specific diet is recommended at this time. In this narrative review we examine the pathophysiology behind specific macronutrient components that can either promote or reverse NAFLD to help inform more specific dietary recommendations. Overall, the data supports reducing saturated fat, refined carbohydrates, and red and processed meats in the diet, and increasing the consumption of plant-based foods. Diets that incorporate these recommendations include plant-based diets such as the Dietary Approaches to Stop Hypertension, Mediterranean, vegetarian, and vegan diets.
Citations
Citations to this article as recorded by
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards Faisal Abaalkhail, Faisal M. Sanai, Khalid AlSwat, Adnan Alzanbagi, Ahmed Aljedai, Ali Alshehri, Assim Alfadda, Hamdan Alghamdi, Majid Almadi, Mohammad Aleissa, Mona Ismail, Saud Alsifri, Turki Alzahrani, Saleh Alqahtani, Waleed Al Hamoudi Saudi Journal of Gastroenterology.2026; 32(2): 104. CrossRef
Exploring the relationship between nutritional status, body composition and health-related quality of life in non-alcoholic fatty liver disease Aiman Khan, Aisha Perveen, Neetu Bansal, Sadia Chishty Nutrition & Food Science.2026; 56(1): 96. CrossRef
The Metabolic Dysfunction–Associated Steatotic Liver Disease–CKD Axis: Intersecting Pathways and Opportunities for Early Intervention Sriram Sriperumbuduri, Prathab Balaji Saravanan, Gaurav Gupta, Arun J. Sanyal Kidney International Reports.2026; 11(4): 103757. CrossRef
A bio-fortified whole tomato food supplement as potential dietary tool for the management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Pier Giorgio Natali, Luisa Imberti, Mauro Piantelli, Marco Minacori, Alessandra Sottini, Erica Gianazza, Cristina Banfi Journal of Translational Medicine.2026;[Epub] CrossRef
Plant-Based and Vegetarian Diets for Weight Loss: A Scoping Review with ☸️SAIMSARA
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH) Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal Nature Reviews Drug Discovery.2025; 24(3): 171. CrossRef
Effectiveness of RESET care program: A real-world-evidence on managing non-alcoholic fatty liver disease through digital health interventions Jayesh Soni, Nikhilesh Pathak, Mihir Gharia, Devina Aswal, Jaymin Parikh, Prachi Sharma, Astha Mishra, Dhvni Lalan, Twinkle Maheshwari World Journal of Hepatology.2025;[Epub] CrossRef
Evaluating the impact of the Dietary Approaches to Stop Hypertension diet versus a calorie‐restricted diet on metabolic dysfunction‐associated steatotic liver disease: A meta‐analysis of randomized controlled trials Fariha Hasan, Avneet Singh, Alexander Garcia, Syeda Hafsa Qadri, Hina Sattar, Rimmel Ali, Hassam Ali, Tommy Nguyen, Babu P. Mohan, Krysta Contino Hepatology Research.2025; 55(4): 515. CrossRef
Liver-related Events and Outcomes in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease Varies With the Type of Cardiometabolic Risk Factor Shekhar Swaroop, Sagnik Biswas, Shubham Mehta, Arnav Aggarwal, Umang Arora, Samagra Agarwal, Amitkumar Chavan, Baibaswata Nayak, Shalimar Journal of Clinical and Experimental Hepatology.2025; 15(5): 102559. CrossRef
Evaluating the RESET care program: Advancing towards scalable and effective healthcare solutions for metabolic dysfunction-associated liver disease Mariana M Ramírez-Mejía, Froylan D Martínez-Sánchez, Jacqueline Córdova-Gallardo, Nahum Méndez-Sánchez World Journal of Hepatology.2025;[Epub] CrossRef
Dietary Intake of Major Minerals and Trace Elements in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: Implications for Dietary Intervention Vasily Isakov, Armida Sasunova, Sergey Morozov, Alexei Goncharov Advances in Therapy.2025; 42(7): 3486. CrossRef
Evidence‐based review of the nutritional treatment of obesity and metabolic dysfunction‐associated steatotic liver disease in children and adolescents Sara Karjoo, Amy Braglia‐Tarpey, Alvin P. Chan, Ana Gabriela Ayala Germán, Rachel E. Herdes, Nikhil Pai, Desiree Sierra‐Velez, Bridget Whitehead, Ruben E. Quiros‐Tejeira, Debora Duro Journal of Pediatric Gastroenterology and Nutrition.2025; 81(3): 485. CrossRef
Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment Hee Yeon Kim, Mary E. Rinella Clinical and Molecular Hepatology.2025; 31(3): 753. CrossRef
Barriers and facilitators to non-pharmacological management of metabolic dysfunction-associated steatotic liver disease: a qualitative evidence synthesis Yusuf Yilmaz Frontiers in Pharmacology.2025;[Epub] CrossRef
The impact of food insecurity on chronic liver disease: A systematic review of the literature Laila M. Elias, Jordy E. Agins, David S. Goldberg, Therese Bittermann, Elena Byhoff Hepatology Communications.2025;[Epub] CrossRef
Gut microbiota heterogeneity in non-alcoholic fatty liver disease: a narrative review of drivers, mechanisms, and clinical relevance Ying Guo, Naisi Zhang, Dongmei Pei Frontiers in Microbiology.2025;[Epub] CrossRef
Gender Differences in Healthy Eating Index as Informed by the Awareness of Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease Wei-Ting Lin, Madeline Novack, Suthat Liangpunsakul, Chiung-Kuei Huang, Hui-Yi Lin, Po-Hung Chen, Tung-Sung Tseng, Peng-Sheng Ting Livers.2025; 5(4): 61. CrossRef
A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease Naim Alkhouri, Katherine Edwards, Mark Berman, Heather Finn, Rafael Escandon, Paul Lupinacci, Nicole Guthrie, Angie Coste, Jesus Topete, Mazen Noureddin Gastro Hep Advances.2024; 3(1): 9. CrossRef
The effects of meal patterns on liver steatosis, fibrosis, and biochemical factors in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial Mohammad Alizadeh, Mohammadreza Mohammad Hosseiniazar, Farkhondeh Alami, Somayyeh Bararnia Adabi Journal of Diabetes & Metabolic Disorders.2024; 23(1): 987. CrossRef
Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population Carolin V. Schneider, Kai Markus Schneider, Anastasia Raptis, Helen Huang, Christian Trautwein, Rohit Loomba Alimentary Pharmacology & Therapeutics.2024; 59(10): 1271. CrossRef
Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges Ernesto Saenz, Nathally Espinosa Montagut, Baohong Wang, Christoph Stein-Thöringer, Kaicen Wang, Honglei Weng, Matthias Ebert, Kai Markus Schneider, Lanjuan Li, Andreas Teufel Engineering.2024; 40: 51. CrossRef
Innovative treatments for obesity and NAFLD: A bibliometric study on antioxidants, herbs, phytochemicals, and natural compounds Salvatore Pezzino, Maria Sofia, Chiara Mazzone, Giorgia Litrico, Luigi Piero Greco, Luisa Gallo, Gaetano La Greca, Saverio Latteri Heliyon.2024; 10(16): e35498. CrossRef
Machine learning uncovers manganese as a key nutrient associated with reduced risk of steatotic liver disease Simon Schophaus, Kate Townsend Creasy, Paul‐Henry Koop, Jan Clusmann, Julius Jaeger, Varnitha Punnuru, Alexander Koch, Christian Trautwein, Rohit Loomba, Tom Luedde, Kai Markus Schneider, Carolin V. Schneider Liver International.2024; 44(10): 2807. CrossRef
Dietary Approaches to Stop Hypertension (DASH) and mortality risk among patients with liver cirrhosis: a prospective cohort study Aida Zarei, Fereshteh Pashayee-khamene, Azita Hekmatdoost, Sara Karimi, Saleheh Ahmadzadeh, Mehdi Saberifiroozi, Behzad Hatami, Zahra Yari BMC Research Notes.2024;[Epub] CrossRef
Common Bean Suppresses Hepatic Ceramide Metabolism in a Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Vanessa K. Fitzgerald, Tymofiy Lutsiv, John N. McGinley, Elizabeth S. Neil, Mary C. Playdon, Henry J. Thompson Nutrients.2024; 16(18): 3196. CrossRef
Non‐alcoholic fatty liver disease: The importance of physical activity and nutrition education—A randomized controlled study Diler Us Altay, Yasemin Kaya, Duygu Mataraci Değirmenci, Emine Kocyiğit, Abdullah Üner, Tevfik Noyan Journal of Gastroenterology and Hepatology.2024; 39(12): 2723. CrossRef
Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study Saba Latif, Tasnim Ahsan Euroasian journal of hepato-gastroenterology.2024; 14(2): 129. CrossRef
Exosomal RBP4 potentiated hepatic lipid accumulation and inflammation in high-fat-diet-fed mice by promoting M1 polarization of Kupffer cells Jin-Mei Yao, Hua-Zhong Ying, Huan-Huan Zhang, Fen-Sheng Qiu, Jun-Qi Wu, Chen-Huan Yu Free Radical Biology and Medicine.2023; 195: 58. CrossRef
Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma Simona Cernea, Danusia Onișor World Journal of Gastroenterology.2023; 29(2): 286. CrossRef
Multi-omics analysis of the effects of dietary changes and probiotics on diet-induced obesity Shiman Jiang, Yuanshuai Su, Qiangqiang Wang, Longxian Lv, Chen Xue, Lvwan Xu, Lanjuan Li Current Research in Food Science.2023; 6: 100435. CrossRef
Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim Frontiers in Endocrinology.2023;[Epub] CrossRef
Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults” Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(1): 179. CrossRef
Effect of exercise-based interventions in nonalcoholic fatty liver disease: A systematic review with meta-analysis Heechul Nam, Jeong-Ju Yoo, Yuri Cho, Seong Hee Kang, Sang Bong Ahn, Hye-Won Lee, Dae Won Jun, Do Seon Song, Miyoung Choi Digestive and Liver Disease.2023; 55(9): 1178. CrossRef
Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management Anja Geerts, Sander Lefere Clinical and Molecular Hepatology.2023; 29(Suppl): S276. CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials Jihyun An, Joo Hyun Sohn Clinical and Molecular Hepatology.2023; 29(Suppl): S268. CrossRef
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review Young-Joo Jin Clinical and Molecular Hepatology.2023; 29(2): 414. CrossRef
The growing burden of non-alcoholic fatty liver disease on mortality Ju-Yeon Cho, Won Sohn Clinical and Molecular Hepatology.2023; 29(2): 374. CrossRef
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith Clinical and Molecular Hepatology.2023; 29(2): 433. CrossRef
Gut Microbiome in the Progression of NAFLD, NASH and Cirrhosis, and Its Connection with Biotics: A Bibliometric Study Using Dimensions Scientific Research Database Salvatore Pezzino, Maria Sofia, Chiara Mazzone, Sergio Castorina, Stefano Puleo, Martina Barchitta, Antonella Agodi, Luisa Gallo, Gaetano La Greca, Saverio Latteri Biology.2023; 12(5): 662. CrossRef
PNPLA3 GENE POLYMORPHISM AND RED MEAT CONSUMPTION INCREASED FIBROSIS RISK IN NASH BIOPSY-PROVEN PATIENTS UNDER MEDICAL FOLLOW-UP IN A TERTIARY CENTER IN SOUTHWEST BRAZIL Silvia Massami YOSHIMURA, Sebastião Mauro Bezerra DUARTE, José Tadeu STEFANO, Daniel Ferraz de Campos MAZO, João Renato Rebello PINHO, Claudia P OLIVEIRA Arquivos de Gastroenterologia.2023; 60(1): 98. CrossRef
Plasma Fatty Acid Composition, Oxidative and Inflammatory Status, and Adherence to the Mediterranean Diet of Patients with Non-Alcoholic Fatty Liver Disease Margalida Monserrat-Mesquida, Maria Magdalena Quetglas-Llabrés, Cristina Bouzas, Oscar Pastor, Lucía Ugarriza, Isabel Llompart, Karla Cevallos-Ibarra, Antoni Sureda, Josep A. Tur Antioxidants.2023; 12(8): 1554. CrossRef
Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease” Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 1050. CrossRef
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies Muthukumaran Jayachandran, Shen Qu Reviews in Endocrine and Metabolic Disorders.2023; 24(6): 1189. CrossRef
Advancing the global public health agenda for NAFLD: a consensus statement Jeffrey V. Lazarus, Henry E. Mark, Quentin M. Anstee, Juan Pablo Arab, Rachel L. Batterham, Laurent Castera, Helena Cortez-Pinto, Javier Crespo, Kenneth Cusi, M. Ashworth Dirac, Sven Francque, Jacob George, Hannes Hagström, Terry T.-K. Huang, Mona H. Isma Nature Reviews Gastroenterology & Hepatology.2022; 19(1): 60. CrossRef
Vaspin attenuates steatosis-induced fibrosis via GRP78 receptor by targeting AMPK signaling pathway Alina Abdolahi, Zakaria Vahabzadeh, Esmael Izadpanah, Mohammad Raman Moloudi Journal of Physiology and Biochemistry.2022; 78(1): 185. CrossRef
Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study Xiaofen Xie, Bing Guo, Xiong Xiao, Jianzhong Yin, Ziyun Wang, Xiaoman Jiang, Jingzhong Li, Lu Long, Junmin Zhou, Ning Zhang, Yuan Zhang, Ting Chen, Baima Kangzhuo, Xing Zhao BMC Public Health.2022;[Epub] CrossRef
Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path! Niki Katsiki, Anca Pantea Stoian, Manfredi Rizzo Clínica e Investigación en Arteriosclerosis.2022; 34: S24. CrossRef
Dietary Patterns and Prevalent NAFLD at Year 25 from the Coronary Artery Risk Development in Young Adults (CARDIA) Study Meagan E. Gray, Sejong Bae, Rekha Ramachandran, Nicholas Baldwin, Lisa B. VanWagner, David R. Jacobs, James G. Terry, James M. Shikany Nutrients.2022; 14(4): 854. CrossRef
Impact of SARS-CoV-2 Lockdown on the Preoperative Care Program of Patients Scheduled for Bariatric Surgery Luigi Schiavo, Pietro Calabrese, Silvana Mirella Aliberti, Salvatore Tramontano, Antonio Iannelli, Vincenzo Pilone Nutrients.2022; 14(7): 1488. CrossRef
Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management Fajuan Rui, Hongli Yang, Xinyu Hu, Qi Xue, Yayun Xu, Junping Shi, Jie Li Infectious Microbes and Diseases.2022; 4(2): 49. CrossRef
Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path! Niki Katsiki, Anca Pantea Stoian, Manfredi Rizzo Clínica e Investigación en Arteriosclerosis (English Edition).2022; 34: 23. CrossRef
Adherence to Mediterranean Diet and NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study Sofía Montemayor, Catalina M. Mascaró, Lucía Ugarriza, Miguel Casares, Isabel Llompart, Itziar Abete, María Ángeles Zulet, J. Alfredo Martínez, Josep A. Tur, Cristina Bouzas Nutrients.2022; 14(15): 3186. CrossRef
Physiopathology of nonalcoholic fatty liver disease: from diet to nutrigenomics Paola Meneghel, Elisa Pinto, Francesco Paolo Russo Current Opinion in Clinical Nutrition & Metabolic Care.2022; 25(5): 329. CrossRef
Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease Ananta Shrestha, Shrijana Pradhananga Euroasian Journal of Hepato-Gastroenterology.2022; 12(S1): S51. CrossRef
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N Journal of Hepatology.2022; 77(6): 1482. CrossRef
Implementation of a Whole Food Plant Based Diet in a Food as Prevention Program in a Resource Constrained Environment Subhas C. Ganguli, Lindsey A. Russell, Keith S. Tsoi Journal of Lifestyle Medicine.2022; 12(3): 148. CrossRef
Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review Kiarash Riazi, Mark G. Swain, Stephen E. Congly, Gilaad G. Kaplan, Abdel-Aziz Shaheen Nutrients.2022; 14(21): 4556. CrossRef
Metabolic drivers of non-alcoholic fatty liver disease Kendra K. Bence, Morris J. Birnbaum Molecular Metabolism.2021; 50: 101143. CrossRef
Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development Pau Vancells Lujan, Esther Viñas Esmel, Emilio Sacanella Meseguer Nutrients.2021; 13(5): 1442. CrossRef
Integrative Behandlungsansätze bei chronischen Lebererkrankungen Roman Huber Zeitschrift für Komplementärmedizin.2021; 13(02): 14. CrossRef
Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome Han Ah Lee, Jihwan Lim, Hyung Joon Joo, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Do-Sun Lim, Kwan Soo Byun, Yeon Seok Seo Clinical and Molecular Hepatology.2021; 27(3): 463. CrossRef
Defining comprehensive models of care for NAFLD Jeffrey V. Lazarus, Quentin M. Anstee, Hannes Hagström, Kenneth Cusi, Helena Cortez-Pinto, Henry E. Mark, Michael Roden, Emmanuel A. Tsochatzis, Vincent Wai-Sun Wong, Zobair M. Younossi, Shira Zelber-Sagi, Manuel Romero-Gómez, Jörn M. Schattenberg Nature Reviews Gastroenterology & Hepatology.2021; 18(10): 717. CrossRef
Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial Won Myung Lee, Jea Hurn Bae, Young Chang, Sae Hwan Lee, Ji Eun Moon, Soung Won Jeong, Jae Young Jang, Sang Gyune Kim, Hong Soo Kim, Jeong-Ju Yoo, Young Seok Kim Nutrients.2021; 13(12): 4453. CrossRef
Reduction of Visceral Adiposity as a Predictor for Resolution of Nonalcoholic Fatty Liver in Potential Living Liver Donors Sunyoung Lee, Kyoung Won Kim, Jeongjin Lee, Taeyong Park, Hyo Jung Park, Gi‐Won Song, Sung‐Gyu Lee Liver Transplantation.2021; 27(10): 1424. CrossRef
Influence of Dietary Behaviors on Dyslipidemia in Pregnant Women and Its Effects on Physical Development of Fetuses and Infants: A Bidirectional Cohort Study Chenyang Li, Xuening Li, Dan Wu, Qi Chen, Zhe Xiao, Deliang Wen, Lingling Zhai, Lihong Jia Nutrients.2021; 13(10): 3398. CrossRef
The effects of Ramadan intermittent fasting on liver function in healthy adults: A systematic review, meta-analysis, and meta-regression MoezAlIslam Faris, Haitham Jahrami, Dana Abdelrahim, Nicola Bragazzi, Ahmed BaHammam Diabetes Research and Clinical Practice.2021; 178: 108951. CrossRef
Dieckol Decreases Caloric Intake and Attenuates Nonalcoholic Fatty Liver Disease and Hepatic Lymphatic Vessel Dysfunction in High-Fat-Diet-Fed Mice Kyung-A Byun, Seyeon Oh, Myeongjoo Son, Chul-Hyun Park, Kuk Hui Son, Kyunghee Byun Marine Drugs.2021; 19(9): 495. CrossRef
Hepatic-Metabolite-Based Intermittent Fasting Enables a Sustained Reduction in Insulin Resistance in Type 2 Diabetes and Metabolic Syndrome Markus Rohner, Robert Heiz, Simon Feldhaus, Stefan R. Bornstein Hormone and Metabolic Research.2021; 53(08): 529. CrossRef
Fasting, Nutrition and Weight Loss: An Approach to Refine Non-Alcoholic Fatty Liver Disease Galal A. AL-SAMHARI, Gaber M. AL-MUSHIKI, Rashi TAMRAKAR, Gibirima ABDULLAHI, YUE-Dong LIN, XIAN-Yan TANG Journal of Nutritional Science and Vitaminology.2021; 67(6): 366. CrossRef
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Wo Clinical and Molecular Hepatology.2021; 27(3): 363. CrossRef
The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC) Ajit Venniyoor, Abdul Aziz Al Farsi, Bassim Al Bahrani Cureus.2021;[Epub] CrossRef
Kee Woon Kweon , Hong Joo Kim , Soong Hwan Lee , Yeong Jung Cho , Jong Cheol Kim , Sung Woo Kim , Hee Soo Kim , In Gyu Back , Cheol Hun Jung , Yong Hyeon Jo , Chang Woo Gham , Dong Ho
Aim s : The purpose of this study was to explore the differences of general characteristics and nutritional factors such as anthropometry and dietary intake between alcohol-related cirrhosis and virus-related liver cirrhosis and to assess the nutritional status of both of these groups. Methods : In this study, the nutritional status of 67 patients with liver cirrhosis (25 with alcohol-related and 42 with virus-related) was evaluated by using clinical assessment, anthropometric measurements, dietary intakes, and biochemical indices. Results : Although anthropometric measurements were not significantly different between alcoholic cirrhosis and viral cirrhosis, anthropometry of patients with viral cirrhosis had a higher tendency than that of alcoholic cirrhotic patients. Alcohol intake factors such as amount, duration, and frequency in alcoholic cirrhotic patients were higher than those in patients with viral cirrhosis. Energy excluding alcohol and vitamin C were significantly different between patients with alcoholic and viral cirrhosis. All subjects had lower intake of energy excluding alcohol, protein, vitamin A, thiamin, riboflavin, niacin, calcium, and iron as than recommended by the Recommended Dietary Allowances (RDA) for Koreans. Of special note was the fact that the intakes of energy excluding alcohol, vitamin A, riboflavin, and calcium were less than 75% of RDA for Koreans. Although the glucose and triglyceride levels were significantly different between alcoholic and viral cirrhotic patients, there were within normal range in both groups. There was an interaction effect in triceps skinfold thickness of the subjects according to both etiology and severity of liver disease. Conclusion : These data suggests that nutritional disorders are common in patients with both alcohol-and virus-related cirrhosis. It is necessary to educate patients with cirrhosis about the importance of a balanced dietary intake as well as its pattern, and quality of diet. (Korean J Hepatol 2000;6:59-72)
Background/Aims The experimental production of cholesterol gallstone suggests that alteration of the nature of gallbladder mucus may be a factor in the induction of gallbladder stones. This study was designed to clarify the changes of the gallbladder epithelia and the role of a high cholesterol-cholic acid diet (CCD) in the formation of the gallstones. Method: Forty mice were fed on a diet of natural 1% high-cholesterol egg yolk and 2.5% cholic acid for 8 weeks. The mice were sacrificed biweekly and followed up for 8 weeks. The gallbladder tissues and bile were prepared for electron microscopic examination. We observed the ultrastructural changes of the epithelia and the sediments of the gallbladder bile with scanning and transmission electron microscopic observation. Results: 1) Process of Gallstone formation in bile: At the 2nd week in mice fed with CCD, the crystals grew up by appositional layering into monoliths and then by aggregation into mulberry-shaped stones. At the 8th week many stones and numerous concrements were observed. 2) Scanning electron microscopic findings: In mice fed with CCD, the scattered whitish patches of epithelial cell surfaces exhibited the cauliflower-like apical protrusion secreting mucin. These protrusions appeared to be swellings of the apical plasmalemma and they were mixed with the mucus and microvilli. 3) Transmission electron microscope findings: At the 2nd week, numerous electron lucent secretory granules were observed in the apical zone of the epithelial cells. Increased numbers of fat vacuoles were also observed in the basal area of epithelium. Two types of cells were observed in the lining epithelium: dark and light cells. Conclusion: This study suggests that long-term administration of CCD, and the resultant increased secretion of glycoprotein from gallbladder epithelial cells, could be a factor in the induction of the gallstones.
Background/Aims ErbB receptor proteins are transmembrane tyrosine kinase receptors; when they are
activated by interaction with ligands, they generate diverse cellular responses, especially during lesion
development and progression to cancer. In this study the expression of ErbB receptors and TGF-α were
investigated using an experimental cirrhosis rat model giving rise to hepatocellular neoplasms, similar to human
liver diseases. Methods: Fifty three male rats received intraperitoneal injection of diethylnitrosamine (DEN, 50
mg/kg), weekly for 18 weeks. Until the eighth week, two rats were sacrificed every two weeks and from the
tenth to the eighteenth week, five rats were sacrificed weekly. Grossly, dyschromatic and dysmorphic nodules
were counted and categorized into three groups: N1/N2/N3: 3 mm≤x<5 mm/5 mm≤x<10 mm/x≥10 mm in
diameter. All nodules were examined, histologically. Antibodies for GSTp, TGF-α, EGF-R, ErbB2, ErbB3 and
ErbB4 were used for immunohistochemistry. Results: The onset of cirrhoses was noted from the twelfth week.
Preneoplastic foci, hepatocellular adenomas (HCA) and hepatocellular carcinomas (HCC) were noted from the
second, eleventh and fifteenth week, respectively. The nodules (N1/N2/N3: 397/258/64) included regenerating
nodule; RN (N1/N2/N3: 72.3%/15.9%/0%), HCA (N1/N2/N3: 27.2%/82.2%/7.6%) and HCC (N1/N2/N3: 0.5%/
1.9%/92.4%). EGF-R was expressed in 12.5% of RN, 64.7% HCA and 75.2% HCC. TGF-α was expressed in
92.4% of RN, 91.3% HCA and 93.2% HCC. Sixty eight percent of TGF-α expressing nodules showed
concurrent EGF-R expression. ErbB2 was expressed in 83.6% of RN, 72.9% HCA and 88.7% HCC. ErbB4 was
expressed in 95.2% of RN, 86.3% HCA and 62.5% HCC. Conclusions: Increased expression of EGF-R and
decreased expression of ErbB4, might be related with tumor progression during DEN-induced
hepatocarcinogenesis. (Korean J Hepatol 2007;13:70-80)
First
Prev
